CBD and NSAIDs: how I thought about the transition away from them
Bottom line. I was on NSAIDs for years as part of my RA management. CBD was part of how I eventually reduced reliance on them, not by swapping one for the other overnight, but by understanding what each was doing and working with my prescriber on the transition. The pharmacology matters here: most NSAIDs are CYP2C9-metabolized, and CBD inhibits CYP2C9. For occasional OTC-dose ibuprofen or naproxen, the interaction risk is low but present. For chronic prescription-dose NSAIDs (diclofenac, indomethacin, celecoxib), the concern is higher, both from CYP2C9 overlap and from the dose-dependent GI and cardiovascular risks that follow higher NSAID plasma levels. Celecoxib has its own page, see CBD and Celebrex.
Key takeaways
- Most NSAIDs (ibuprofen, naproxen, diclofenac) use CYP2C9 primarily, the same enzyme CBD inhibits, so the pharmacokinetic overlap is direct.
- For occasional OTC doses: the risk is real but modest. Short duration and low dose mean the exposure change from CYP inhibition is small.
- For chronic prescription-dose NSAIDs: the concern scales up. GI and cardiovascular risks that are already dose-dependent get compounded if plasma levels rise.
- Aspirin (low-dose, irreversible COX-1) is not a CYP2C9 substrate, different mechanism, lower pharmacokinetic concern.
- Topical NSAIDs (Voltaren gel) deliver diclofenac with much lower systemic absorption than oral, worth knowing if localized joint pain is the goal.
What the science says
Bansal 2023's n=18 RCT confirmed CBD raises CYP2C9 substrate plasma exposure significantly at research doses. Stöllberger 2023's review of 403 CYP-substrate drugs lists ibuprofen, naproxen, and diclofenac as CYP2C9 substrates with meaningful CBD overlap. No NSAID-specific case reports in the literature parallel the Cortopassi warfarin case — but the mechanism is the same enzyme.
Per-NSAID profile
| NSAID | Brand | CYP metabolism | CBD concern |
|---|---|---|---|
| Ibuprofen | Advil, Motrin | CYP2C9 (primary) | Low-moderate; OTC occasional use lower risk |
| Naproxen | Aleve, Naprosyn | CYP2C9 (primary) | Low-moderate; similar profile to ibuprofen |
| Diclofenac | Voltaren | CYP2C9 (primary) | Moderate — prescription-dose, longer half-life |
| Indomethacin | Indocin | CYP2C9 + glucuronidation | Moderate — prescription, complex metabolism |
| Celecoxib | Celebrex | CYP2C9 (COX-2 selective) | Moderate - see dedicated page |
| Aspirin (low-dose) | Bayer, generic | Not CYP2C9 (esterase, glucuronidation) | Lower pharmacokinetic risk; different mechanism |
Context matters: OTC vs chronic prescription use
The interaction risk is dose-dependent and context-dependent. Taking 400mg ibuprofen once or twice for a headache while using CBD daily is unlikely to produce a clinically significant effect — the CBD's CYP2C9 inhibition slows ibuprofen clearance somewhat, but the short duration and low dose mean the cumulative exposure change is minimal.
Taking 800mg ibuprofen three times daily for chronic arthritis pain while on CBD is a different calculation: chronic NSAID use already carries GI (gastric ulceration) and cardiovascular (blood pressure, platelet) risk that is dose-dependent. If CBD consistently raises NSAID plasma levels, those risks compound. This is the scenario that warrants a prescriber conversation.
What this means for you
- Occasional OTC NSAIDs: Low risk. Use the lowest effective dose and shortest duration — which is the right guidance for NSAIDs regardless of CBD.
- Chronic prescription NSAIDs: Tell your prescriber. Mention your CBD dose and format. The prescriber can assess whether monitoring makes sense.
- GI protection. If you take chronic NSAIDs, you may already be on a proton pump inhibitor. This remains appropriate regardless of CBD. If you develop dark or bloody stools, severe abdominal pain, vomiting blood, chest pain, sudden severe headache, or one-sided weakness while on NSAIDs, call 911 (or your local emergency number) immediately — do not wait to contact your prescriber.
- Consider the NANO roll-on. For localized joint pain - which is often why people reach for ibuprofen - the NANO roll-on is a topical option that doesn't carry GI risk and has minimal systemic CYP exposure. It's not a substitute for systemic anti-inflammatory therapy, but for local muscle and joint use, it's a different risk profile.
Frequently asked questions
Can I take CBD with ibuprofen or naproxen?
For occasional OTC use: the risk is real but low. Ibuprofen and naproxen both use CYP2C9; CBD inhibits CYP2C9. A single 400mg ibuprofen once in a while while on daily CBD is unlikely to produce a clinically significant effect, the duration and dose are small. For chronic prescription-dose use (800mg three times daily for months), the calculation is different and warrants a prescriber conversation.
Can CBD replace NSAIDs?
I moved away from NSAIDs over time, but it was a gradual process with my prescriber's involvement, not a replacement. The honest answer is that CBD hasn't been shown to replace NSAIDs in head-to-head clinical trials. What I found was that CBD helped enough with symptom management that my reliance on NSAIDs decreased. Whether that's replicable for anyone else is individual. Don't stop NSAIDs without your prescriber's guidance.
Does CBD and ibuprofen combination increase GI risk?
Indirectly, yes, if CBD raises ibuprofen plasma levels via CYP2C9 inhibition, you're pharmacokinetically getting a higher effective NSAID dose, which increases GI exposure. NSAIDs' GI risk (gastric irritation, ulceration) is dose-dependent. Take NSAIDs with food, use the lowest effective dose, and if you're on long-term NSAIDs, a proton pump inhibitor conversation with your prescriber is appropriate regardless of CBD.
References
- Bansal S et al. (2023). Cannabidiol effects on the pharmacokinetics of substrates of cytochrome P450 enzymes. PMID 37313955
- Stöllberger C, Finsterer J. (2023). Interactions between cannabidiol and commonly used prescription drugs. PMID 37541924
- Nachnani R et al. (2024). Cannabidiol-prescription drug interactions: a systematic review. PMID 38868665